Hypofractionated stereotactic radiotherapy in the management of recurrent or residual medulloblastoma/PNET
Authors:
- Frank SaranFSFrank Saran
- Antonia L. CreakACAntonia L. Creak
- Alan P. WarringtonAWAlan P. Warrington
- Daphne TraishDTDaphne Traish
- Michael BradaMBMichael Brada
- 9 January 2008
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 50 (3) , 554-560
Abstract
Purpose: To evaluate the efficacy and toxicity of hypofractionated stereotactic radiotherapy in the management of locally recurrent or residual central nervous system (CNS) primitive neuroectodermal tumors (PNETs).Patients and Methods: Between 1991 and 2005, 12 patients with locally recurrent medulloblastoma and two patients with residual supratentorial PNET were treated with hypofractionated stereotactic conformal radiotherapy (SCRT). Nine patients were treated for first recurrence, two patients after the 2nd, and one patient after 3rd recurrence. Median age at diagnosis was 20 years (range: 4–35 years) and median age at SCRT 25 years (range: 7–41 years). Nine of 12 patients underwent resection at recurrence and 13 patients received at least one cycle of chemotherapy prior to SCRT. All received focal SCRT (30–40 Gy/6–8 #) using non‐coplanar arcs (n = 6) or fixed conformal non‐coplanar fields (n = 8).Results: Median overall survival was 29 months (95% CI: 6–51 months) and median progression‐free survival was 12 months (95% CI: 5–19 months). Local progression‐free survival at 1 and 3 years was 80% (95% CI: 55–100%) and 48% (95% CI: 11–85%). Causes of death were recurrent CNS disease (n = 7), herpes encephalitis (n = 1), and metastatic PNET outside the CNS (n = 1).Conclusion: Hypofractionated SCRT provides effective local control with acceptable toxicity for patients with recurrent localized PNET. However, overall long‐term disease control is rare and limited by the occurrence of CSF mediated relapses, which thus could benefit from intensive systemic chemotherapy as part of the primary relapse strategy even in local recurrences. Larger multi‐national studies will be necessary to assess the value of such combined treatment approaches. Pediatr Blood Cancer 2008;50:554–560.Keywords
This publication has 40 references indexed in Scilit:
- Surveillance neuroimaging of intracranial medulloblastoma in children: how effective, how often, and for how long?Journal of Neurosurgery, 2003
- Possible benefits of high-dose chemotherapy and autologous stem cell transplantation for adults with recurrent medulloblastomaBone Marrow Transplantation, 2002
- Adult Medulloblastoma: Prognostic Factors and Patterns of RelapseNeurosurgery, 2000
- Medulloblastoma: Clinical and biologic aspectsNeuro-Oncology, 1999
- Hyperfractionated craniospinal radiotherapy and adjuvant chemotherapy for children with newly diagnosed medulloblastoma and other primitive neuroectodermal tumorsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1996
- Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International society of paediatric oncology (SIOP) and the (German) society of paediatric oncology (GPO): SIOP IIMedical and Pediatric Oncology, 1995
- Medulloblastoma in adultsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1995
- Results of Radiosurgery in the Management of Recurrent and Residual MedulloblastomaPediatric Neurosurgery, 1995
- The change in patterns of relapse in medulloblastomaCancer, 1991
- Medulloblastoma: freedom from relapse longer than 8 years — a therapeutic cure?Journal of Neurosurgery, 1991